Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

ChemoCentryx Completes IPO

ChemoCentryx, Inc. (CCXI) said Monday that it has completed its initial public offering of 4.5 million shares of common stock.

In addition, the underwriters of the initial public offering exercised their over-allotment option in full and purchased an additional 675,000 shares of common stock.

All of such shares were sold by ChemoCentryx at an initial public offering price of $10.00 per share.

J.P. Morgan and Citigroup acted as joint book-running managers of the offering, and Cowen and Company acted as co-manager of the offering.

Click here to receive FREE breaking news email alerts for NYSE Euronext and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
This apparel maker has doubled its earnings per share in just two years and increased its annual earnings forecast from time to time, despite a challenging consumer spending environment. Contributions from acquisitions, efficiency gains from self-owned global supply chain and benefits from 'Innovate-to-Elevate' strategy continue to boost the company's results. Here is a quick summary of the earnings reported after the bell on Nov 20. We have 20+ stocks listed here. The good news is you can skip this step. There is a next move that can make your life a lot easier. Our research team has already done the groundwork for you. All these stocks listed... Design software maker Autodesk, Inc. said Thursday after the markets closed that its third quarter profit fell 81% from last year, as higher costs and expenses more than offset an 11% increase in revenue. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations as did its quarterly revenue.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.